Warfarin treatment among Finnish patients with atrial fibrillation: Retrospective registry study based on primary healthcare data

BMJ Open

Volumn 4, Issue 2, 2014, Pages

  Hallinen, Taru ^a   Soini, Erkki J ^a   Asseburg, Christian ^a   Kuosmanen, Pekka ^b   Laakkonen, Ari ^b  

^a Esior Oy   (Finland)

^b Department of Health and Social Welfare ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; DRUG COST; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT CARE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; VERY ELDERLY; ATRIAL FIBRILLATION; CLINICAL PRACTICE; ECONOMICS; REGISTER; STATISTICS AND NUMERICAL DATA;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FINLAND; HEALTH CARE COSTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; REGISTRIES; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84897550810     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004071     Document Type: Article

References (34)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001;285:2370-5. (Pubitemid 32424106)
2. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
3. Atrial Fibrillation, Current Care Guideline, 10.1.2012. Working group appointed by the Finnish Medical Society Duodecim and the Finnish Cardiac Society. Helsinki.http://www.terveysportti.fi/xmedia/hoi/hoi50036.pdf (accessed 22 Nov 2012).
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
5. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
7. Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79:1428-34.
8. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19.
9. Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51.
10. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005;39:446-51. (Pubitemid 40276873)
11. Hallinen T, Martikainen JA, Soini EJ, et al. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006;22:683-92.
12. Björholt I, Andersson S, Nilsson GH, et al. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract 2007;8:6.
13. Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010;8:2192-200.
14. You JH, Tsui KK, Wong RS, et al. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 2012;7:e39640.
15. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333.
16. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70.
17. Official Statistics of Finland (OSF). Population structure [e-publication]. ISSN=1797-5395. Helsinki: Statistics Finland. http://www.stat.fi/til/vaerak/index-en.html (accessed 9 Oct 2012).
18. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al . A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9. (Pubitemid 23069000)
19. Puhakka J. ed Antikoagulaatiohoidon käsikirja, ohjeistus varfariinihoidon toteutuksesta (Handbook on anticoagulation treatment, Guidance on implementing warfarin treatment). Tampere: Juvenes Print - Tampereen yliopistopaino Oy, 2011.
20. Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41.
21. Hujanen T, Kapiainen S, Tuominen U, et al. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006 (Health care unit costs in Finland year 2006). Stakesin työpapereita 3. Helsinki: Valopaino Oy, 2008.
22. Official Statistics of Finland (OSF). Price index of public expenditure [e-publication]. Helsinki: Statistics Finland. http://tilastokeskus.fi/til/jmhi/ index-en.html (accessed 26 Oct 2012).
23. Griswold M, Parmigiani G, Potosky A, et al. Analyzing health care costs: a comparison of statistical methods motivated by medicare colorectal cancer charges. Biostatistics 2004;1:1-23.
24. Wieloch M, Själander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011;32:2282-9.
25. Malik AK, Taylor AJ. Can warfarin randomized trials be reproduced in "real life"? Adherence to warfarin guidelines for intensity of anticoagulation in a university based warfarin clinic. South Med J 2000;93:58-61. (Pubitemid 30058990)
26. Dimberg I, Grzymala-Lubanski B, Hägerfelth A, et al. Computerised assistance for warfarin dosage - effects on treatment quality. Eur J Intern Med 2012;23:742-4.
27. Helin T, Metso T, Lassila R, et al. INR testing results at the community clinics in the Hospital District of Helsinki and Uusimaa (article in Finnish). Suomen Lääkärilehti (Finnish Medical Journal) 2012;67:1569-74.
28. Leskelä R-L, Schmidt M, Hirsso P, et al. Implementation of anticoagulant treatment in Oulu city outpatient care (article in Finnish). Suomen Lääkärilehti 2013;68:1481-6.
29. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
30. Menotti A, Lanti M, Puddu P, et al. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000;84:238-44.
31. Müller-Nordhorn J, Binting S, Roll S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-26. (Pubitemid 351768126)
32. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
33. Laatikainen T, Jula A, Salomaa V. Verenpaine Suomessa - FINRISKI-tutkimuksen tuloksia (hypertension in Finland - results of the FINRISK-study). Tutkimuksesta tiiviisti 2. Helsinki; National Institute for Health and Welfare, 2012.
34. Mikkola T, Nemlander A, Tyni T. Keskisuurten kuntien sosiaali - ja terveystoimen kustannukset vuonna 2011. Suomen Kuntaliitto. Helsinki: Kuntatalon paino, 2012.